What the FDA labels say about taking them together
Rolapitant and warfarin
Rolapitant's FDA label of August 19, 2020 names warfarin in its drug interactions section; the warfarin label PlainMeds reads does not name rolapitant. The rolapitant label: “Although co-administration of intravenous rolapitant, which has a higher C max than oral VARUBI, with warfarin did not substantially increase the systemic exposure to S-warfarin, the active enantiomer, the effects on …”
Check it at the source: the rolapitant FDA label on DailyMed (effective August 19, 2020, TerSera Therapeutics LLC); the warfarin FDA label on DailyMed (effective May 29, 2026, Amneal Pharmaceuticals LLC).
What does the rolapitant label say about warfarin?
Rolapitant label, drug interactionsWarfarin Clinical Impact: Although co-administration of intravenous rolapitant (…), which has a higher C max than oral VARUBI, with warfarin did not substantially increase the systemic exposure to S-warfarin, the active enantiomer, the effects on INR and prothrombin time were not studied. Intervention: Monitor INR and prothrombin time and adjust the dosage of warfarin, as needed with concomitant use of VARUBI, to maintain the target INR range.
Source: FDA drug label (Varubi), TerSera Therapeutics LLC, effective August 19, 2020 (SPL set a52896cd-4a98-49b8-82db-bf1985a64d97), via openFDA; the full label on DailyMed
What does the warfarin label say about rolapitant?
Warfarin's label (effective May 29, 2026) does not name rolapitant in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Warfarin Sodium), Amneal Pharmaceuticals LLC, effective May 29, 2026 (SPL set 558b7a0d-5490-4c1b-802e-3ab3f1efe760), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Rolapitant | Warfarin | |
|---|---|---|
| Labeled for | n/a | Blood clots (DVT and PE), Atrial fibrillation |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | n/a | $0.093 per tablet 2 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once